HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

T-Cell Prolymphocytic Leukemia (Leukemia, T Cell, Chronic)

Subscribe to New Research on T-Cell Prolymphocytic Leukemia

A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.

Also Known As:

Leukemia, T Cell, Chronic; Leukemia, Prolymphocytic, T-Cell; Leukemia, Lymphocytic, Chronic, T Cell; Leukemia, Lymphocytic, Chronic, T-Cell; Lymphocytic Leukemia, T Cell, Chronic; Lymphocytic Leukemia, T-Cell, Chronic; T-Cell Leukemia, Chronic; T-Lymphocytic Leukemia, Chronic; Leukemia, T-Cell Prolymphocytic; Leukemias, T-Cell Prolymphocytic; Prolymphocytic Leukemia, T-Cell; Prolymphocytic Leukemias, T-Cell; T Cell Prolymphocytic Leukemia; T-Cell Prolymphocytic Leukemias; Leukemia, T-Cell, Chronic

Networked: 65 relevant articles (8 outcomes, 5 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
3.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
4.	Hematologic Neoplasms (Hematological Malignancy)
5.	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)

Experts

1.	Herling, Marco: 5 articles (04/2015 - 11/2005)
2.	Jones, Dan: 4 articles (02/2008 - 08/2004)
3.	Ravandi, Farhad: 3 articles (01/2008 - 11/2005)
4.	Trümper, Lorenz: 2 articles (11/2014 - 01/2009)
5.	Matutes, Estella: 2 articles (11/2011 - 01/2002)
6.	Dearden, Claire E: 2 articles (11/2011 - 01/2002)
7.	Catovsky, Daniel: 2 articles (11/2011 - 01/2002)
8.	Rassidakis, George Z: 2 articles (02/2008 - 08/2004)
9.	Medeiros, L Jeffrey: 2 articles (02/2008 - 08/2004)
10.	Konopleva, Marina: 2 articles (01/2008 - 09/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to T-Cell Prolymphocytic Leukemia:

1.	alemtuzumab (Campath)FDA Link 09/15/2001 - "High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H." 11/24/2011 - "Intravenous alemtuzumab is an effective and well-tolerated treatment for T-cell prolymphocytic leukemia (T-PLL). " 11/24/2011 - "Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route." 01/01/2014 - "A 72-year-old woman with known T-cell prolymphocytic leukemia treated with a course of alemtuzumab presented to our department with a VH in her left eye after a fall. " 07/01/2012 - "Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia."
2.	fludarabineIBA 01/01/2012 - "Epstein-Barr virus-negative classical Hodgkin's lymphoma in a patient with T-cell prolymphocytic leukemia treated with fludarabine." 06/15/2013 - "Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia."
3.	Cladribine FDA LinkGeneric 05/01/1995 - "Complete remission in T-cell prolymphocytic leukemia with 2-chlorodeoxyadenosine."
4.	Mitoxantrone (Novantrone)FDA LinkGeneric 06/15/2013 - "Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia."
5.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/15/2013 - "Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia."
6.	Phosphotransferases (Kinase)IBA 04/17/2015 - "Interleukin-2-inducible T-cell kinase (ITK) targeting by BMS-509744 does not affect cell viability in T-cell prolymphocytic leukemia (T-PLL)." 09/22/2006 - "Recently, we demonstrated that the proto-oncogene TCL1, overexpressed in human T-cell prolymphocytic leukemia, is an Akt kinase co-activator. " 12/17/2004 - "We have demonstrated previously that TCL1 (a proto-oncogene underlying human T cell prolymphocytic leukemia) interacts with Akt and functions as an Akt kinase co-activator. " 01/01/2013 - "Protooncogene T-cell leukemia 1 (TCL1), which is implicated in human T-cell prolymphocytic leukemia (T-PLL), interacts with Akt and enhances its kinase activity, functioning as an Akt kinase co-activator. "
7.	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/01/2008 - "High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia." 12/01/2001 - "T-cell receptor gammadelta T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype." 01/01/1986 - "We investigated the rearrangement patterns of the gene coding for the beta chain of the T cell receptor (T beta) in 11 patients with T-cell derived chronic lymphoproliferative disorders, including T-cell prolymphocytic leukemia (T-PLL) and T-cell chronic lymphocytic leukemia (T-CLL). "
8.	Carbon MonoxideIBA 09/22/2006 - "Recently, we demonstrated that the proto-oncogene TCL1, overexpressed in human T-cell prolymphocytic leukemia, is an Akt kinase co-activator. " 12/17/2004 - "We have demonstrated previously that TCL1 (a proto-oncogene underlying human T cell prolymphocytic leukemia) interacts with Akt and functions as an Akt kinase co-activator. " 01/01/2013 - "Protooncogene T-cell leukemia 1 (TCL1), which is implicated in human T-cell prolymphocytic leukemia (T-PLL), interacts with Akt and enhances its kinase activity, functioning as an Akt kinase co-activator. "
9.	PerforinIBA 09/01/1996 - "Perforin-positive leukemic cell infiltration in the aortic tissue of a patient with T-cell prolymphocytic leukemia." 08/01/1995 - "Here we report a rare case of T-cell prolymphocytic leukemia in whom leukemic killer cells, expressing a cytolytic factor perforin, infiltrated the heart. " 08/01/1995 - "Perforin-positive leukemic cell infiltration in the heart of a patient with T-cell prolymphocytic leukemia." 09/01/1996 - "Here we report a rare case of T-cell prolymphocytic leukemia in which leukemic killer cells, expressing a cytolytic factor perforin, infiltrated the aorta as well as the heart and may have directly injured aortic vascular cells which strongly expressed human leukocyte antigens (HLAs) and intercellular adhesion molecule-1 (ICAM-1) as well as costimulatory molecules B7 and B70, which are ligands for CD28 expressed on T-cells. "
10.	Oncogene Proteins (Oncogene Protein)IBA 02/15/2008 - "T-cell prolymphocytic leukemia (T-PLL) is consistently associated with inactivation of the ATM gene and chromosomal re-arrangements leading to an overexpression of MTCP1/TCL1 oncoproteins. " 02/15/1998 - "Crystal structure of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel beta-barrel topology."

Therapies and Procedures

1.	Stem Cell Transplantation 03/01/2015 - "Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation?" 11/01/2007 - "Successful treatment of T-cell prolymphocytic leukemia with full-intensity conditioning followed by matched unrelated donor allogeneic stem cell transplantation." 04/01/2006 - "Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission." 12/01/2013 - "In this paper, we report a case of a 61-year-old female who underwent nonmyeloablative allogenic stem cell transplantation for T-cell prolymphocytic leukemia and subsequently developed biopsy proven minimal change disease shortly after cessation of her immunosuppression therapy. "
2.	Transplants (Transplant) 04/01/2006 - "Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission."
3.	Drug Therapy (Chemotherapy) 11/01/2014 - "T-cell prolymphocytic leukemia is a rare aggressive malignancy with low susceptibility to conventional chemotherapy. " 05/01/2005 - "T-cell prolymphocytic leukemia has an aggressive course with short median survival and poor response to chemotherapy. " 09/15/2001 - "T-cell prolymphocytic leukemia (T-PLL) is a chemotherapy-resistant malignancy with a median survival of 7.5 months. " 07/01/2012 - "The aim of this study was to evaluate the cost-effectiveness of alemtuzumab (CAMPATH-1H) compared with conventional chemotherapy in people with T-cell prolymphocytic leukemia (T-PLL). " 01/01/2002 - "Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed."
4.	Intravenous Infusions 06/01/2015 - "We gave intravenous infusions of Resimmune 2.5 - 11.25 μg/kg over 15 minutes to 30 patients (25 with cutaneous T-cell lymphoma, 3 with peripheral T-cell lymphoma, 1 with T-cell large granular lymphocytic leukemia and 1 with T-cell prolymphocytic leukemia) in an inter-patient dose escalation trial. "
5.	Splenectomy 11/01/1999 - "Improvement of quality of life after splenectomy in an HTLV-I carrier with T-cell prolymphocytic leukemia." 07/01/1993 - "Between February, 1970 and September, 1991, we performed splenectomies on 70 patients with chronic lymphoproliferative disorders including primary leukemias: 19 B-cell chronic lymphocytic leukemia, 1 B-cell prolymphocytic leukemia, 22 hairy cell leukemias, 4 large granular lymphocytic leukemias, 1 T-cell prolymphocytic leukemia, and non-Hodgkin's lymphomas (NHL): 10 splenic lymphomas with villous lymphocytes, 4 follicular lymphomas, 5 mantle cell lymphomas, 3 lymphoplasmacytic and 1 large cell NHL. "